OMER Omeros Corp: ערך חשבונאי של החברה
Omeros Corporation brings together elite immunologists and biochemists united by the goal of treating rare diseases. The business relies on the development of MASP-2 inhibitors for the treatment of renal and hematological pathologies, covering the immunology segment. This price chart on GURU.Markets, where the indicator is -0.05, illustrates the company's dependence on external investments and patents due to the lack of profitable products currently in the development stage.
OMER (Omeros Corp.): פילוחים אנליטיים ודוחות לפי אינדיקטורים
Book value represents the value of a company's net assets minus all liabilities. This metric is calculated by aggregating public equity data, reflecting the fundamental "anchor" of value. Monitoring book value allows for an assessment of the business's internal resilience to market volatility. However, for Omeros Corporation (OMER), this indicator is critical. FDA delays regarding narsoplimab create a real threat of funding shortages for debt servicing.